This metastatic allograft model serves as a highly relevant syngeneic representation of intraperitoneal high-grade serous TP53- and BRCA2-mutated ovarian carcinoma, suitable for evaluating PARPi (olaparib) efficacy [40]. The gene discussed is BRCA2; the disease is ovarian carcinoma.